| pubmed-article:8306367 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8306367 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8306367 | lifeskim:mentions | umls-concept:C0008972 | lld:lifeskim |
| pubmed-article:8306367 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8306367 | lifeskim:mentions | umls-concept:C0021760 | lld:lifeskim |
| pubmed-article:8306367 | lifeskim:mentions | umls-concept:C1268930 | lld:lifeskim |
| pubmed-article:8306367 | lifeskim:mentions | umls-concept:C0020846 | lld:lifeskim |
| pubmed-article:8306367 | lifeskim:mentions | umls-concept:C0022687 | lld:lifeskim |
| pubmed-article:8306367 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:8306367 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:8306367 | lifeskim:mentions | umls-concept:C0006560 | lld:lifeskim |
| pubmed-article:8306367 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:8306367 | lifeskim:mentions | umls-concept:C2709199 | lld:lifeskim |
| pubmed-article:8306367 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:8306367 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:8306367 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8306367 | pubmed:dateCreated | 1994-3-15 | lld:pubmed |
| pubmed-article:8306367 | pubmed:abstractText | Interleukin-6 (IL-6) is a cytokine that acts on a variety of cell types, including myeloid progenitor cells and B and T lymphocytes. It has been found to activate cytotoxic T cells and natural killer (NK) cells and to induce T-cell-mediated antitumour effects in animal models. In a phase I clinical trial of recombinant human IL-6, 20 patients with advanced cancer were entered to receive daily subcutaneous injections of IL-6 over 7 days followed by a 2-week observation period and another 4 weeks of daily IL-6 injections. Doses varied between 0.5 microgram/kg and 20 micrograms/kg body weight and immune functions were monitored throughout. At all dose levels IL-6 administration led to a marked increase in serum levels of C-reactive protein and a moderate rise in complement factor C3. The proportions of CD4, CD8 or HLA-DR lymphocytes in peripheral blood did not alter with IL-6 treatment nor did the in vitro proliferation of peripheral blood mononuclear cells induced by either phytohaemagglutinin, pokeweed mitogen or fixed Staphylococcus aureus. By contrast, NK cell activity, lymphokine-activated killer (LAK) cell activity and proliferation induced by in vitro culture with interleukin-2 (IL-2) were suppressed at doses exceeding 2.5 micrograms/kg. Serum IgE levels were consistently elevated over the IL-6 dose range but IgM, IgG and IgA levels were unaffected. In summary there is a dose-dependent induction of acute-phase proteins by in vivo IL-6 treatment. At higher IL-6 doses there is a suppressive effect on NK and LAK activity measured in vitro. IL-6 may thus be useful in combination cytokine therapies that seek to suppress LAK and favour cytotoxic T lymphocyte responses. The rise in IgE levels in response to IL-6 was unexpected and suggests a more pivotal role than previously known for the control of IgE production; this could include IgE-related diseases. | lld:pubmed |
| pubmed-article:8306367 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8306367 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8306367 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8306367 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8306367 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8306367 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8306367 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8306367 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8306367 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8306367 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:8306367 | pubmed:issn | 0340-7004 | lld:pubmed |
| pubmed-article:8306367 | pubmed:author | pubmed-author:YoungRR | lld:pubmed |
| pubmed-article:8306367 | pubmed:author | pubmed-author:ScarffeJ HJH | lld:pubmed |
| pubmed-article:8306367 | pubmed:author | pubmed-author:SternP LPL | lld:pubmed |
| pubmed-article:8306367 | pubmed:author | pubmed-author:ScheitSS | lld:pubmed |
| pubmed-article:8306367 | pubmed:author | pubmed-author:FitzsimmonsLL | lld:pubmed |
| pubmed-article:8306367 | pubmed:author | pubmed-author:McDermottRR | lld:pubmed |
| pubmed-article:8306367 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8306367 | pubmed:volume | 38 | lld:pubmed |
| pubmed-article:8306367 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8306367 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8306367 | pubmed:pagination | 119-26 | lld:pubmed |
| pubmed-article:8306367 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8306367 | pubmed:meshHeading | pubmed-meshheading:8306367-... | lld:pubmed |
| pubmed-article:8306367 | pubmed:meshHeading | pubmed-meshheading:8306367-... | lld:pubmed |
| pubmed-article:8306367 | pubmed:meshHeading | pubmed-meshheading:8306367-... | lld:pubmed |
| pubmed-article:8306367 | pubmed:meshHeading | pubmed-meshheading:8306367-... | lld:pubmed |
| pubmed-article:8306367 | pubmed:meshHeading | pubmed-meshheading:8306367-... | lld:pubmed |
| pubmed-article:8306367 | pubmed:meshHeading | pubmed-meshheading:8306367-... | lld:pubmed |
| pubmed-article:8306367 | pubmed:meshHeading | pubmed-meshheading:8306367-... | lld:pubmed |
| pubmed-article:8306367 | pubmed:meshHeading | pubmed-meshheading:8306367-... | lld:pubmed |
| pubmed-article:8306367 | pubmed:meshHeading | pubmed-meshheading:8306367-... | lld:pubmed |
| pubmed-article:8306367 | pubmed:meshHeading | pubmed-meshheading:8306367-... | lld:pubmed |
| pubmed-article:8306367 | pubmed:meshHeading | pubmed-meshheading:8306367-... | lld:pubmed |
| pubmed-article:8306367 | pubmed:meshHeading | pubmed-meshheading:8306367-... | lld:pubmed |
| pubmed-article:8306367 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8306367 | pubmed:articleTitle | Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. | lld:pubmed |
| pubmed-article:8306367 | pubmed:affiliation | CRC Department of Immunology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK. | lld:pubmed |
| pubmed-article:8306367 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8306367 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8306367 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:8306367 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8306367 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8306367 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8306367 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8306367 | lld:pubmed |
